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Classification 
Colorectal Cancer (CRC) can be classified from the 
molecular or etiological point of view: 
Molecular pathway 
- Chromosome instability (CIN) 
-- 85% of all CRCs 
-- Somatic inactivation of APC, p53; 
- Microsatellite instability (MSI) 
-- 15% of all CRCs 
-- Hypermethylation or somatic inactivation of DNA 
repair enzymes; 
Etiology 
- Sporadic CRC 
-- 84% microsatellite stable (MSS) CRC 
-- 10% microsatellite instable (MSI) CRC; 
- Hereditary CRC 
-- 1% Familial Adenomatous Polyposis (FAP) (MSS 
CRC) 
-- 5% Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC) (MSI CRC). 
In the last years, downstream molecules of different 
pathways such as KRAS and BRAF are included in 
proposals for a more differentiated molecular 
classification of CRC. 
The CpG Methylator Phenotype (CIMP) status also 




Clinics and pathology 
Etiology 
According to the WHO Classification of Tumors of the 
Digestive System the following factors may play an 
etiological role in the development of CRC: 
- Diet (high caloric food, meat consumption) 
- Obesity 
- Sedentary lifestyle 
- Smoking 
- Alcohol consumption 
- Inflammatory Bowel Disease (IBD) 
-- Cohn's disease 
-- Ulcerative colitis. 
Epidemiology 
The following epidemiologic data are based on the 
WHO Classification of Tumors of the Digestive 
System: 
- In 2008, 1.23 million new CRC cases occurred 
worldwide (9.7% of all new cancers). 
- CRC is the 4th most frequent cancer in men and 3rd in 
women. 
- Higher rates occur in industrialized, high-resource 
countries (40-60 per 100000). 
- Incidence increases with age. 
- Rates of colon cancer are about 20% higher and rectal 
cancer about 50% higher in men than in women. 
- Worldwide mortality rate is about 50% of the 
incidence rate. 
 










- Change bowel habits including constipation and 
diarrhea 
- Melena 
- Abdominal pain 
- Anemia due to chronic low-grade bleeding 




The histological diagnosis of CRC is based on the 
invasion through the muscularis mucosae into the 
submucosa. 
The different histological subtypes include: 
- Adenocarcinoma 
-- Mucinous adenocarcinoma 
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-- Signet ring cell carcinoma 
-- Medullary carcinoma 
-- Serrated adenocarcinoma 
-- Cribriform comedo-type adenocarcinoma 
-- Micropapillary adenocarcinoma 
- Adenosquamous carcinoma 
- Spindle cell carcinoma 
- Squamous cell carcinoma 
- Undifferentiated carcinoma. 
The gold standard for staging is the TNM classification 
proposed by the UICC/AJCC. 
Important parameters included in the TNM 
classification are: 
- T : Primary Tumor 
- N: Regional Lymph Nodes 
- M: Distant Metastasis 
- G: Histopathological grading 
- L: Lymphatic invasion 
- V: Venous invasion 
- Pn: Perineural invasion. 
Molecular features in Pathology that can be important 
in the daily diagnostic practice are: 
- Microsatellite status: Determined by 
immunohistochemistry and/or PCR 
- KRAS status: Determined by PCR 
- BRAF status: Determined by PCR. 
Treatment 
Surgery is the primary therapy of CRC. 
Adjuvant therapy: 
- Colon Cancer: Chemotherapy 
- Rectal Cancer: Chemo- and radiotherapy 
- Anti-EGFR therapy: dependent on the KRAS 
mutational status. 
Prognosis 
The prognosis is mainly based on the TNM staging 
system (see Pathology section). 
Additional prognostic factors can be: 
- Tumor border configuration 
- Tumor budding 
- Tumor regression grade 
- Bowel perforation 
- Intra- and peritumoral inflammation 
- Circumferential resection margin 




- Loss of heterozygosity 
- CEA level 
- miRNA 
- CIMP status. 
Cytogenetics 
Cytogenetics Morphological 
There are two types of colorectal cancers, according to 
the ploidy: 
Aneuploid tumors showing numerous allelic losses; 
Aneuploidy, loss and rearrangements of chromosome 
1p (about 70%), 5q (55%, loss of APC), 15q, 18q 
(65%, loss of DCC), 17p (80%, TP53), and 17q (30%); 
and abnormalities in 7q (25%) and 8p (55%). 
Reciprocal translocation t(5;10)(q22;q25), 
inv(5)(q22q31.3). 
Diploid tumours without frequent allelic losses. 
Genes involved and proteins 
Note 
Extensive data on the genetic background of tumor 
progression in colorectal cancer (CRC) is available 
based on molecular pathology methods including 
genome wide sequencing. Alterations in oncogenes and 
tumor suppressor genes are intricately involved in the 
development and progression of CRC, some of which 
are strong predictors of treatment response to targeted 
therapies and chemotherapeutics. In the following, a 
comprehensive overview of both hereditary and 
somatic genetic changes in CRC is provided including 
genetic changes causing DNA mismatch repair 
deficiency as well as genomic alterations leading to 
deregulation of the WNT, RTK/Ras/MAPK, PI3K, 
TGF-Beta and P53 signaling pathways. 
Mismatch repair 
MLH1 (mutL homolog 1, colon cancer, 
nonpolyposis type 2 (E. coli)) 
Location 
3p22.3 
DNA / RNA 
19 exons, 2524 bp mRNA. 
Protein 
Involved in mismatch repair (MMR) process after 
DNA replication. Forms heterodimer with PMS2 (also 
known as MutLα). This heterodimer is responsible for 
downstream MMR events such as strand 
discrimination, recruiting proteins needed for excision 
and resynthesis. 
Germinal mutations 
Most frequent cause of Lynch syndrome (also known 
as HNPCC). Over 300 mutations have been described 
(nucleotide substitutions or insertions/substitutions) 
resulting in a truncated protein. Hereditable germline 
epimutations have also recently been reported. 
The full penetrance of Lynch syndrome requires the 
biallelic "double hit" inactivation of the responsible 
MMR gene (see also MSH2, MSH6 and PMS2) for 
tumor development. 
Somatic mutations 
Mutation is rare; usually epigenetic modification due to 
methylation which results in MSI-H status. Methylation 
of MLH1 is by far the most frequent cause of sporadic 
MSI-H in CRC. 
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MLH3 (mutL homolog 3 (E. coli)) 
Location 
14q24.3 
DNA / RNA 
12 exons, 2 major mRNA transcripts: 7911 and 7839 
bp. 
Protein 
Involved in mismatch repair process after DNA 
replication. Competes against PMS2 to form 
heterodimer with MLH1 (MutLγ) which assists MutLα. 
Germinal mutations 
Only few MLH3 germline mutations have been 
described in Lynch syndrome, by far most of which 
amino acid substitutions. Implications are still unclear.  
To date, there is no evidence that these germline 
mutations cause the full Lynch syndrome phenotype. 
Somatic mutations 
Shows insertions/deletions usually in A(8) repeats in 
MSH-H tumors. Considered to be a secondary mutation 
which is believed to further increase genetic instabili y. 
MSH2 (mutS homolog 2, colon cancer, 
nonpolyposis type 1 (E. coli)) 
Location 
2p21 
DNA / RNA 
16 exons, mRNA transcript 3145 bp. 
Protein 
Involved in mismatch repair process after DNA 
replication. Binds to MSH6 or MSH3 to form the 
MutSα or MutSβ complex. The MutS complex 
associates with the MutL complex composed of MLH 
and PMS2. 
Germinal mutations 
Frequent cause of Lynch syndrome. Over 300 
mutations have been described (nucleotide substitutions 
or insertions/substitutions) resulted in a truncated 
protein. Hereditable germline epimutations have also 
recently been reported. 
Somatic mutations 
Rare; sporadic MSH2 mutations have been described in 
sporadic MSI-H cases. Somatic methylation usually 
occurs as a "second hit" of the wild-type allele in cases 
with germline mutation. 
MSH3 (mutS homolog 3 (E. coli)) 
Location 
5q14.1 
DNA / RNA 
24 exons with 2 mRNA transcripts of 5 and 3.8 kb. 
Protein 
Involved in post-replicative DNA mismatch repair. 
Binds with MSH2 to form the MutSβ heterodimer, 
which recognizes large insertion-deletion loops. Forms  
 
a ternary complex with MutLα after mismatch binding. 
Germinal mutations 
Mostly LOH and missense variants, seen in MSI-L 
tumors. 
Somatic mutations 
Hypermethylation has been described in other tumors 
such as endometrial carcinoma. Functional impairment 
of MSH3 is probably not required for the formation f 
MMR-deficient tumors but is selected for during tumor 
progression. 
MSH6 (mutS homolog 6 (E. coli)) 
Location 
2p16 
DNA / RNA 
10 exons, mRNA transcript 4435 bp. 
Protein 
Involved in post-replicational DNA mismatch repair. 
Forms heterodimer with MSH2 (MutSα). 
Germinal mutations 
A less frequent cause of Lynch syndrome with variable 
penetration. Deletion and frameshift mutation result in 
a truncated protein. Can be associated with so-called 
early-onset CRC or Lynch syndrome with atypical 
features, such as endometrial cancer. 
Somatic mutations 
Mutation or epigenetic activation is rare in CRC. 
PMS2 (PMS2 postmeiotic segregation 
increased 2 (S. cerevisiae)) 
Location 
7p22.1 
DNA / RNA 
15 exons, mRNA transcript 2851bp. 
Protein 
Involved in post-replicational DNA mismatch repair. 
Forms the MutLα complex together with MLH1. 
Germinal mutations 
Mostly deletions, some missense variants, most 
mutations are unique. Mutation gives rise to Lynch 
syndrome, probably of lower penetrance than in 
germline MLH1 and MSH2 mutations. Previously 
thought to be very rare in Lynch syndrome primarily 
due to technical difficulties in analysis. Mutations have 
recently been found to occur frequently using newly 
developed detection methods. 
Somatic mutations 
Probably very rare, putative somatic mutation reported. 
Supposedly last mismatch repair gene to undergo 
methylation. 
POLE (polymerase (DNA directed), 
epsilon, catalytic subunit) 
Location 
12q24.3 
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DNA / RNA 
19 exons. 
Protein 
Member of the Family B DNA polymerases consisting 
of 4 subunits. Participates in chromosomal DNA 
replication, recombination as well as DNA repair via 
base excision and nuclear excision. 
Germinal mutations 
Sequence alterations, mainly in the catalytic subunit 
including the proofreading domain have been found in 
MLH1-mutant CRC. It has been suggested that 
defective polymerase proofreading can contribute to the 
mutator phenotype as a "booster" in CRC. 
WNT-Signaling 
APC (adenomatous polyposis coli) 
Location 
5q21-q22 
DNA / RNA 
16 exons, 10702 bp mRNA. 
Protein 
Tumor suppressor protein composed of 2843 amino 
acids; the APC gene product interacts with the adherens 
junction proteins α- and β-catenin suggesting 
involvement in cell adhesion. APC may also inhibit the
pathway regulated by the beta-catenin/Tcf complex.  
Other functions include anterior-posterior pattern 
formation, axis specification, cell cycle, cell migration, 
apoptosis, chromosome segregation and spindle 
assembly. 
Germinal mutations 
Point mutations in APC gene results in the generation 
of stop codons, small deletions, LOH, 1-2 bp insertions. 
Most mutations result in a truncated protein, mostly in 
the first half. Results in FAP and AFAP. 
Somatic mutations 
The APC gene is mutated in about 50% of sporadic 
colorectal tumors. Most mutations are frameshifts or 
nonsense mutations resulting in premature stop codons.  
Some mutations in beta-catenin have been described in 
tumors and cell lines without mutations in the APC 
gene. APC loss may also be due to interstitial deletion 
or mitotic recombination, LOH, and nonsense 
mutations.  
Most of the somatic mutations are clustered in the exon 
15 in mutation cluster region (MCR).  
About 20% of APC mutations are observed with 
mutation of TP53. Methylation of the promoter may be 
related. 




DNA / RNA 
12 exons, 3762 bp mRNA. 
Protein 
Human DKK1 is a potent inhibitor of WNT signaling 
over interaction with LRP5 and LRP6. 
Somatic mutations 
Genomic alterations (inactivation) are found in up to 
33% of hypermutated CRC and 4% of non-
hypermutated CRC cases. 
LRP5 (low density lipoprotein receptor-
related protein 5) 
Location 
11q13.4 
DNA / RNA 
23 exons, 5161 bp mRNA. 
Protein 
LRP5 encodes a transmembrane low density 
lipoprotein receptor (1615 amino acids). It acts as a co-
receptor with FZD10 on the cell surface, forming a 
Wnt-LRP5-LRP6-FZD10 complex for signal 
transduction of Wnt proteins.  
Signal transduction is mediated by an intracellular 
PPP(S/T)P motif, which is phosphorylated following 
WNT activation.  
The phosphorylated intracellular PPP(S/T)P motif then 
serves as a docking site for AXIN2. 
Somatic mutations 
Genomic alterations (inactivation) are infrequent i 
CRC and are found in <1% of hypermutated CRC and 
up to 10% of non-hypermutated cases. 
FZD10 (frizzled family receptor 10) 
Location 
12q24.33 
DNA / RNA 
1 exon, intronless, 3282 bp mRNA. 
Protein 
Encodes a 581 amino acid protein; member of the 
frizzled gene family seven-transmembrane-type WNT 
protein receptors. Acts as part of the Wnt-LRP5-LRP6-
FZD10 receptor complex for signal transduction of 
WNT proteins. Upregulation leads to increased WNT 
signaling activity, inhibition of β-catenin degradation 
and accumulation of β-catenin in the cytoplasm. 
Somatic mutations 
Genomic alterations (activation) are found in 19% of 
non-hypermutated CRC and 13% of hypermutated 
CRC cases. Frequent events include overexpression of 
FZD10, in one series in up to 17% of cases. 
AXIN1 (axin 1) 
Location 
16p13.3 
DNA / RNA 
10 exons, 3675 bp mRNA. 
Protein 
Encodes an 862 amino acid protein. AXIN1 is an 
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important component of the beta-catenin destruction 
complex binding GSK3B, FAM123B and CTNNB1 (β-
catenin). AXIN stabilizes this complex, which supports 
the hyperphosphorylation of β-catenin by GSK3B, 
followed by ubiquitination and degradation. AXIN 
thereby negatively regulates Wnt signaling; 
consequently loss of AXIN expression would be 
predicted to lead to decreased phosphorylation and 
degradation of β-catenin, causing increased WNT-
signaling. 
Somatic mutations 
Limited data available. AXIN1 mutations (frequently 
missense mutations) have been described in up to 11% 
of colorectal cancer cases. 
AXIN2 (axin 2) 
Location 
17q23-q24 
DNA / RNA 
10 exons, 4259 bp mRNA. 
Protein 
Encodes an 843 amino acid protein. Part of the axin
protein family; Substitutes for AXIN1 as an importan  
component of the beta-catenin destruction complex 
binding GSK3B, FAM123B and CTNNB1 (β-catenin). 
Germinal mutations 
Limited evidence suggests that germline mutations in 
AXIN2 may increase the risk for development of CRC. 
Somatic mutations 
Axin2 is frequently mutated in MMR deficient CRC 
cells. The mutations result in the stabilization of beta 
catenin. Genomic alterations are infrequent in non-
hypermutated CRC. In hypermutated CRC up to 23% 
of cases show inactivation of the AXIN2 locus. 




DNA / RNA 
2 exons, 7500 bp mRNA. 
Protein 
Encodes an 1135 amino acid protein. Forms the β-
catenin destruction complex together with CTNNB1, 
GSK3B, AXIN1/AXIN2. Mutation is thought to 
contribute to the stabilization of β-catenin in CRC. 
Interacts with WT1. 
Somatic mutations 
The FAM123B gene contains a T6-microsatellite in the 
N-terminal coding region and is infrequently mutated 
in the setting of mismatch repair deficiency due to 
frame shift mutations (described in 5% of MSI cases in 
one series). More recent studies by the Cancer Genom  
Atlas Network have indicated genomic alterations 
(inactivation) in approximately 7% of non-
hypermutated CRC and 37% of hypermutated CRC 
cases. Further, FAM123B shows inactivating mutations 
in approximately 30% of Wilms tumors. 
CTNNB1 (catenin (cadherin-associated 
protein), beta 1, 88kDa) 
Location 
3p21 
DNA / RNA 
16 exons, 3362 bp mRNA. 
Protein 
Encodes the 781 amino acid protein β-catenin. β-
catenin functions as partner of E-cadherin in the 
formation of adherens junctions. Further, it is a central 
target of Wnt-signaling: In absence of Wnt-signaling, 
b-catenin forms a complex with APC, GSK-3 and 
Axin; Complex formation leads to phosphorylation of 
β-catenin through the action of GSK-3, which leads to 
degradation of the protein through the ubiquitin system. 
In case of APC mutation, β-catenin accumulates in the 
cell cytoplasm and translocates into the nucleus, where 
it has been shown to associate with transcription factors 
of the T cell factor-lymphoid enhancer factor (Tcf-Lef) 
family. This is assumed to lead to activation of genes 
involved in the positive regulation of epithelial to 
mesenchymal transition, proliferation and inhibition f 
apoptosis. 
Germinal mutations 
Germline inactivating mutations of the APC gene lead 
to the FAP syndrome. 
Somatic mutations 
Inactivating mutations in the APC gene represent early 
events in the chromosomal instability pathway of CRC. 
APC mutation leads to dissociation of the β-catenin- 
APC-GSK-3-Axin complex, and reduced 
phosphorylation and degradation of β-catenin. Genomic 
alterations (inactivation) are frequent in CRC, and are 
mostly due to biallelic inactivation of the APC gene, 
found in approximately 80% of non-hypermutated CRC 
and 50% of hypermutated CRC cases. 
TCF7L2 (transcription factor 7-like 2 (T-
cell specific, HMG-box)) 
Location 
10q25.2 
DNA / RNA 
17 exons, predicted mRNA: 1490 bp. 
Protein 
Encodes a 619 amino acid transcription factor 
containing a high mobility group box; Interacts with 
CTNNB1 in the Wnt signaling pathway; Acts on 
numerous Wnt targeted genes containing a TCF7L2 
binding domain. 
Somatic mutations 
In colorectal cancer cell lines, VTI1A-TCF7L2 fusions 
have been identified, supporting anchorage independent 
tumor growth. In CRC, genomic alterations 
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(inactivation) are found in approximately 12% of non-
hypermutated CRC and 30% of hypermutated CRC 
cases. 
FBXW7 (F-box and WD repeat domain 




DNA / RNA 
10 exons, 3927 bp mRNA. 
Protein 
Encodes a 707 amino acid protein representing the 
variable F-box subunit of the SCF (SKP1-cullin-F-box) 
complex which functions as an ubiquitin ligase. 
FBXW7 acts as a tumor suppressor and is involved in 
the ubiquitination and degradation of the cell cycle 
regulators Cyclin E and c-Myc; further targets include 
notch intracellular domain (NICD), c-Myb, NOTCH1 
and presenilin 1. Experimentally, loss of FBXW7 leads 
to accumulation of β-catenin; Further, mutation of 
FBXW7 has been suggested to increase cell 
proliferation. 
Germinal mutations 
Somatic mutations of FBXW7 in HNPCC and FAP 
patients have been described. The frequency of 
FBXW7 mutations in FAP and HNPCC corresponded 
to patients with sporadic carcinomas. 
Somatic mutations 
Somatic mutations have been described in ovarian and 
breast cancer cell lines. In CRC, genomic alterations 
(inactivation) are found in approximately 10% of non-
hypermutated CRC and 43% of hypermutated CRC 
cases. 




DNA / RNA 
3 exons, 3963 bp mRNA. 
Protein 
Encodes a 509 amino acid protein which contains a 
high-mobility-group (HMG) domain; Acts as a 
transcription factor and inhibits CTNNB1 (β-catenin) 
activity; In particular, the SOX9 product has been 
shown to interfere with the activation of β-catenin 
dependent gene targets and acts as a promoter beta-
catenin ubiquitinylation and degradation; important in 
skeletal development. 
Somatic mutations 
In CRC, genomic alterations of SOX9 are infrequently 
described. Genomic alterations are found in  
 
 
approximately 4% of non-hypermutated CRC and 7% 
of hypermutated CRC cases. 
TGFβ-Signaling 
TGFBR1 (transforming growth factor, 
beta receptor 1) 
Location 
9q22 
DNA / RNA 
9 exons, complex locus; transcription produces 11 
different mRNAs. 
Protein 
The 503 amino acid TGFBR1 proteins form a 
homodimer and associate with TGFBR2 homodimers 
to form the TGF-beta receptor; Both subunits of the
TGF-beta receptor, TGFBR1 and TGFBR2, act as 
transmembrane serine/threonine kinases. After binding 
of the TGF-beta cytokine dimers TGFB1, TGFB2 or 
TGFB3, the TGFBR2 and TGFBR1 form a stable 
receptor complex; TGFBR2 is a constitually active type 
II transmembrane serine/threonine kinase and 
phosphorylates TGFBR1 (a type I receptor) upon 
ligand binding. The TGFBR1 serine/threonine kinase 
binds and phosphorylates SMAD2, a receptor-
associated signaling molecule. SMAD2 dissociates 
from the receptor and interacts with SMAD4; the 
SMAD2/SMAD4 complex then translocates into the 
nucleus and modifies the transcription of TGF-beta 
regulated genes. TGF-beta mediated signaling has been 
shown to have anti-proliferative effects on epithelia, 
mesenchymal and hematopoietic cells and to modulate 
cell-stroma interactions. Physiologic TGF-beta 
signaling promotes cell differentiation and can induce 
apoptosis. In cancer cells, TGF-beta signaling is 
frequently disrupted by mutations in the receptor or 
downstream mediators turning off the signaling 
pathway; In the tumor microenvironment, TGF-beta 
modulates tumor-host interaction by increasing 
angiogenesis and converting T-effector cells into 
immunosuppressive Regulatory T-cells, thereby 
supporting tumor progression and inhibiting the anti-
tumoral immune defense. In conjunction with IL-6, 
TGF-beta has been shown to induce the differentiation 
of Th17 cells. 
Germinal mutations 
An increased prevalence of SNPs in the TGFBR1 locus 
resulting in decreased TGFBR1 allelic expression (up 
to 9.3% of cases) have been shown in patients with 
colorectal cancer. 
Somatic mutations 
In CRC, genomic alterations (inactivation) of TGFBR1 
are frequent in patients with hypermutated CRC (17%). 
Genomic alterations of the TGFBR1 locus are 
infrequently observed in patients with non-
hypermutated CRC (<1%). 
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TGFBR2 (transforming growth factor, 
beta receptor II (70/80kDa)) 
Location 
3p22 
DNA / RNA 
8 exons, 2094 bp mRNA. 
Protein 
Encodes a 567 amino acid protein which forms a 
homodimer and associates with TGFBR1 to form the 
TGF-beta type II receptor.  
Possesses serine/threonine kinase function and 
activates SMAD2 and SMAD3 by phosphorylation. 
Activated SMAD2 forms a heterodimer with SMAD4 
to form a complex which translocates into the nucles 
and modulates the transcription of TGF-beta regulated 
genes. 
Somatic mutations 
The TGFBR2 gene locus contains a poly A 
mononucleotide tract in the coding region, which is 
frequently mutated in MSI-high CRC (up to 74%), 
leading to inactivation of the gene.  
TGFBR2 mononucleotide mutations have not shown an 
impact on outcome in initial studies. Inactivation f 
TGFBR2 by point mutation has been demonstrated in 
up to 15% of MSS CRC cases in initial studies.  
More recent studies by the Cancer Genome Atlas 
Network have indicated genomic alterations 
(inactivation) in approximately 2% of non-
hypermutated CRC and 43% of hypermutated CRC 
cases. 
SMAD2 (SMAD family member 2) 
Location 
18q21.1 
DNA / RNA 
12 exons, 10384 bp mRNA. 
Protein 
Encodes a 467 amino acid protein; Downstream 
signaling molecule of TGF-Beta signaling. SMAD2 is 
phosphorylated by the heteromeric TGF-beta type II 
receptor serine/threonine kinase domain. SMAD2 
forms a dimer with SMAD4 followed by translocation 
into the nucleus; the SMAD2/SMAD4 dimer then 
modifies the transcription of TGF-Beta target genes by 
forming a transcription repressor complex. 
Somatic mutations 
Somatic mutations of SMAD2 have been described in 
3.4% of sporadic CRC, mostly causing missense 
changes in the protein which reduces SMAD2/SMAD4 
complex formation. Joint biallelic hits are common.  
Recent studies by the Cancer Genome Atlas Network 
indicate inactivating genomic alterations in 6% of n n-
hypermutated CRC and 13% in hypermutated cases. 
 
 
SMAD3 (SMAD family member 3) 
Location 
15q22.33 
DNA / RNA 
9 exons, 5808 bp mRNA. 
Protein 
Encodes a 425 amino acid protein; Downstream 
signaling molecule of TGF-Beta and activin signaling. 
Phosphorylated by the heteromeric TGF-beta type II 
receptor serine/threonine kinase and the activin type 1 
receptor kinase domain. SMAD3 forms a dimer with 
SMAD4 followed by translocation into the nucleus; the 
SMAD3/SMAD4 dimer then modifies the transcription 
of TGF-Beta target genes. 
Somatic mutations 
Somatic mutations of SMAD3 have been described in 
4.3% of sporadic CRC. Missense changes in the protein 
lead to reduced association with SMAD4 by alteration 
of the phosphorylation regulated Ser-Ser-X-Ser motifs 
within SMAD3. Further, mutations cause reduced 
SMAD3 transcriptional activity. Joint biallelic hits are 
common. Recent data from the Cancer Genome Atlas 
Network indicate infrequent genomic alterations in 2%
of non-hypermutated CRC. Inactivating genomic 
alterations are described in up to 17% of hypermutated 
cases. 
SMAD4 (SMAD family member 4) 
Location 
18q21.1 
DNA / RNA 
13 exons, 3202 bp mRNA. 
Protein 
The SMAD4 protein is coded from 11 exons and 
contains 552 amino acids. SMAD4 forms a  
heterodimer with phosphorylated SMAD2 or SMAD3 
and translocates into the nucleus. The 
SMAD2/SMAD3-SMAD4 complex then forms a 
transcription repressor complex and modifies 
transcription of TGF-Beta target genes. 
Germinal mutations 
Results in juvenile polyposis with an approximate 
lifetime risk of 40% for development of CRC. 
Somatic mutations 
Somatic mutations of SMAD4 have been described in 
8.6% of sporadic CRC. Missense changes in the protein 
structure reducing the association with SMAD2 in the
SMAD2/4 complex. Joint biallelic hits are common. 
Recent studies by the Cancer Genome Atlas Network 
indicate inactivating genomic alterations in 15% of 
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ACVR2A (activin A receptor, type IIA) 
Location 
2q22.3 
DNA / RNA 
11 exons, 5217 bp mRNA. 
Protein 
The 513 amino acid ACVR2A proteins forms a 
homodimer (type IIa receptor subunit) and associate 
with ACVR1B homodimers (type IB receptor subunit) 
to form the Activin receptor; Both ACVR2A and 
ACVR1B act as transmembrane serine/threonine 
kinases. After binding of activin A, activin B or inhibin 
A, which belong to the TGF-Beta protein superfamily, 
ACVR2A and ACVR1B form a stable receptor 
complex; ACVR2A is a type II transmembrane 
serine/threonine kinase and phosphorylates ACVR1B 
(a type I receptor) upon ligand binding. The ACVR1B 
serine/threonine kinase binds and phosphorylates 
receptor-associated signaling molecule from the SMAD 
family (SMAD2, SMAD3). SMAD2 dissociates from 
the receptor and interacts with SMAD4; the 
SMAD2/SMAD4 complex then translocates into the 
nucleus and modifies the transcription of TGF-beta 
regulated genes. 
Somatic mutations 
Somatic mutations in ACVR2A are particularly 
common in MSI-high CRC. The ACVR2A locus 
encompasses two poly A repeats within the coding 
sequence of exon 3s and 10 which have been shown to 
be mutated in up to 83% of MSI-high CRC leading to 
loss of protein expression in up to 62% of the cases 
with mutations. Further studies have identified 
methylation and LOH of the ACVR2A locus in 
association with loss of protein expression. 
ACVR1B (activin A receptor, type IB) 
Location 
12q13 
DNA / RNA 
7 exons, 2375 bp mRNA. 
Protein 
The 505 amino acid ACVR1B proteins (type IB 
receptor subunit) form the activin receptor complex in 
association with ACVR2A or ACVR2B homodimers 
(type IIa receptor subunit) to form the Activin receptor; 
Act as transmembrane serine/threonine kinases and 
activate receptor-associated signaling molecule from 
the SMAD family (SMAD2, SMAD3). 
Somatic mutations 
Data on genomic alterations in CRC are scarce. Recent 
studies by the Cancer Genome Atlas Network indicate 
frequent inactivating genomic alterations in 20% of 
hypermutated cases. Genomic alterations of the 
ACVR1B locus are infrequently observed in patients  
with non-hypermutated CRC (4%). Frequent somatic 
mutations have been described in pancreatic cancer (up 
to 30%). 
RTK-RAS-Signaling 
ERBB2 (v-erb-b2 erythroblastic 
leukemia viral oncogene homolog 2, 




DNA / RNA 
30 exons, 4478 bp. 
Protein 
The Epidermal Growth Factor Receptor (EGFR) family 
consists of 4 receptor tyrosine kinases, EGFR (ERBB1/ 
HER1), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 
(HER4). ERBB2 encodes a 1255 aa protein that has no 
ligand binding domain of its own and therefore cannot 
bind growth factors. However, it does bind tightly o 
other ligand-bound EGFR family members to form a 
heterodimer, stabilizing ligand binding and enhancing 
kinase-mediated activation of downstream signaling 
pathways. 
Somatic mutations 
Mutations and focal amplifications of ERBB2 in 
colorectal cancers are rare (<5%). As potentially drug-
targetable, the predictive value of ERBB2 
amplifications in these patients remains to be 
determined. 
ERBB3 (v-erb-b2 erythroblastic 




DNA / RNA 
28 exons, 5511 bp. 
Protein 
1342 aa. ERBB3 possesses an extracellular ligand-
binding domain, a transmembrane domain and a 
tyrosine kinase domain. However, the kinase domain 
has no tyrosine kinase activity. Erbb3 therefore can
bind ligand but cannot convey the signal into the cell
through protein phosphorylation. It however does 
dimerize with other EGF receptor family members. 
Somatic mutations 
Mutations in ERBB3 appear only as rare events in 
colorectal cancers. 
KRAS (v-Ki-ras2 Kirsten rat sarcoma 










Atlas Genet Cytogenet Oncol Haematol. 2013; 17(5)  357 
DNA / RNA 
6 exons, 5436 bp. 
Protein 
189 aa. KRAS belongs to the ras gene family 
containing also HRAS and NRAS. The KRAS protein 
is a GTPase that plays a central role in several different 
signal transduction pathways. In colorectal cancer, 
ligand binding and heterodimerization of the EGFR 
leads to activation of the oncogenic Ras-Raf-MEK-
ERK signaling pathway acting on cell proliferation, cell 
survival and tumor angiogenesis. 
Somatic mutations 
Activating point mutations in KRAS occur in 
approximately 30-40% of all patients with colorectal 
cancer and are frequent in exon 2 codons 12 and 13 as 
well as in exon 3 codon 61. These mutations are no 
longer considered to be of prognostic value. Evidence 
suggests that metastatic patients with KRAS mutated 
colorectal cancers undergoing anti-EGFR based 
therapies have a significantly reduced treatment 
response rate compared to patients with wild-type 
tumors. Nonetheless, recent retrospective analyses 
indicate that specific KRAS gene mutations, for 
example, G13D, may confer a degree of responsiveness 
in these patients. 




DNA / RNA 
7 exons, 4461 bp. 
Protein 
189 aa. N-ras belongs to the ras gene family containi g 
also KRAS and HRAS. NRAS is an oncogene that 
encodes a membrane protein with GTPase activity that 
is activated by a guanine nucleotide-exchange factor 
and inactivated by a GTPase activating protein. 
Somatic mutations 
Substitution missense mutations occurring 
predominantly in codons 12, 13 and 61 have been 
reported in <5% of patients with colorectal cancer. 
These mutations may have predictive value as 
biomarkers of non-response in patients treated with 
anti-EGFR based therapies. 
BRAF (v-raf murine sarcoma viral 
oncogene homolog B1) 
Location 
7q34 
DNA / RNA 
18 exons, 2949 bp. 
Protein 
766 aa. Braf is an oncogenic protein and one of three 
Raf kinases that play a role in the Ras-Raf-MEK-ERK 
signaling pathway by phosphorylating MEK. 
Germinal mutations 
BRAF mutations generally do not occur in patients 
with Lynch syndrome associated colorectal cancers 
(HNPCC) and are often used as an exclusion criterion 
for detection of these patients. 
Somatic mutations 
BRAF point mutations in colorectal cancers occur in 9-
12% of all patients. They are commonest in exon 15 
codon 600 (p.V600E).  
BRAF gene mutations are frequently detected in 
patients with microsatellite instability-high (MSI-H) 
colorectal cancers as well as in tumors displaying high-
level CpG Island Methylator Phenotype (CIMP). 
BRAF mutations have been linked to more unfavorable 
survival, often independently of the MSI status; they 
are not predictive of response in patients treated with
anti-EGFR based therapies. 
PI3K-Signaling 




DNA / RNA 
5 exons, 1354 bp mRNA. 
Protein 
Encodes a 180 amino acid protein; member of the 
family of insulin-like polypeptide growth factors 
recognized by the Insulin like growth-factor 1 receptor 
(IGF1R).  
Activation of IGF1R (a receptor tyrosine kinase) leads 
to phosphorylation of insulin-receptor substrates 1 and 
2 (IRS1/IRS2), which contribute to the activation of 
both the PI3K-AKT/PKB pathway and the Ras-MAPK 
pathway.  
PI3K-AKT/PKB regulates cell survival and sensitivity 
to apoptosis; Ras-MAPK signaling controls cell 
proliferation, cell survival and tumor angiogenesis.  
Both pathways play important roles for malignant 
transformation and tumor progression in CRC. 
Somatic mutations 
15-22% of colorectal cancers show overexpression of 
IGF2, which is particularly common in non 
hypermutated, MSS CRC. IGF2 overexpression has not 
been described as a pathogenetic feature of MSI-high 
CRC. 
PIK3CA (phosphatidylinositol-4,5-




DNA / RNA 
21 exons, 3207 bp mRNA. 
Protein 
Encodes a protein predicted with 1068 amino acids, 
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representing the catalytic subunit alpha of class I PI 3-
kinases (PI3K). PI3K are a group of enzymes that ply 
a central function for intracellular signal transduction 
by the generation of phosphatidylinositol 3,4,5-
trisphosphate at the plasma membrane. PI3K generates 
PI3 by phosphorylating phosphatidylinositol 4,5-
diphosphates (PI2) in the plasma membrane which then 
serve as docking sites for proteins containing a 
phosphoinositide-binding domains (e.g. pleckstrin 
homology domains). This includes protein kinase B 
(Akt), thereby triggering the Akt/mTOR pathway. The 
Akt pathway has a central regulatory role and 
pleiotropic effects on cell growth, differentiation and 
proliferation, cell motility and migration as well as the 
regulation of angiogenesis and apoptosis. 
Somatic mutations 
In CRC, activating mutations are frequently observed 
in exon 9 and exon 20 of the PIK3CA locus. Frequency 
of genomic alterations ranges from approximately 15% 
in non-hypermutated CRC to 37% in hypermutated 
cases. PIK3CA exon 20 mutations have been correlated 
to a reduced response rate of CRC patients to anti-
epidermal growth factor receptor (EGFR) monoclonal 
antibodies. Further, concomitant exon 9 and exon 20 
mutations have been shown to predict significantly 
worse disease-specific survival while isolated 
mutations in either exon 9 or 20 did not impact survival 
outcome. 




DNA / RNA 
9 exons, 3147 bp mRNA. 
Protein 
Tumor suppressor protein, which negatively regulates 
AKT/PKB signaling. The protein is a dual specificity 
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, 
removing phosphates from serine, tyrosine and 
threonine; Further, PTEN acts as a lipid phosphatase, 
removing phosphate groups from phosphatidylinositol 
3,4,5-trisphosphate, thereby antagonizing PI 3-kinase 
function and negatively regulating the Akt/mTOR 
pathway; PTEN thereby assumes tumor-suppressor 
functions, inhibiting cell growth, proliferation, motility 
and migration and supporting apoptosis in many 
different cancer subtypes. 
Germinal mutations 
Germinal mutations in PTEN are associated with the 
hereditary Cowden Syndrome which is characterized 
by development of multiple hamartomas in skin and 
gastrointestinal tract (intestinal hamartomatous polyps), 
gangliocytoma of the cerebellum and a severely 
increased risk for the development of breast carcinoma, 
non-medullary carcinoma of the thyroid, endometrial 
carcinoma, colorectal cancer, kidney cancer and 
melanoma. 
Further, germinal mutations in PTEN are associated 
with rare hereditary syndromes including Bannayan-
Riley-Ruvalcaba Syndrome, Proteus syndrome and 
Proteus-like syndrome. 
Somatic mutations 
Somatic mutations of PTEN are more frequently 
observed in MSI-high CRC (18% of cases) than MSS 
CRC. Somatic mutations (inactivation) in MSI-high 
CRC are the consequence of frameshift mutations, 
nonsense, missense, and splice-site mutations. 
P53-Signaling 
TP53 (tumor protein p53) 
Location 
17p13 
DNA / RNA 
11 exons, 1179 bp mRNA. 
Protein 
Encodes a 393 amino acid protein. P53, the "master 
watchman of the genome" has central tumor suppressor 
function and an essential role in cell cycle regulation, 
particularly at the G1 DNA damage checkpoint. The 
five highly-conserved gene regions contain a 
transactivation domain, a DNA-binding domain, 
nuclear localization signals and a tetramerization 
domain. Intracellular P53 levels are low in cellular 
homeostasis, but are quickly upregulated in response to 
cellular and oncogenic stress, in particular DNA 
damage. P53 targets genes involved in the cell cycle, 
stopping the progression of the G1 phase (through 
activation of p21) if DNA damage or other stress 
signals are present. 
Germinal mutations 
Results in the autosomal dominant Li-Fraumeni 
Syndrome, which leads to a severely increased risk for 
the development of soft tissue tumors (sarcomas, 
osteosarcomas), brain tumors (glioblastoma) as well as 
hematologic malignancies (leukemia) and epithelial 
malignancy (breast cancer, adrenal cortical carcinoma). 
An increased risk for colorectal carcinomas has been 
described in initial studies, mostly in association with 
missense or nonsense mutations between exons 4-10. 
Somatic mutations 
Mutations of P53 are most frequent in non-
hypermutated cancers (59%), and are mostly located in 
exons 4 to 8 with hotspots at codons 175, 245, 248,73 
and 282.  
Both deletions and insertions as well as missense, non-
sense and splicing mutations have been described 
resulting in a truncated p53 protein. 80% of mutations 
result from deamination of methylated cytosine in CpG 
region of the gene (codons 175, 248 and 273).  
Mutant p53 is found to be overexpressed in primary 
colon cancer. p53 mutation is observed in 40-50% of  
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colorectal carcinomas, and is associated with 
aggressive carcinomas. p53 mutation or LOH of 
chromosome 17p is observed mostly in carcinoma 
rather than adenoma, in both familial and non-familial 
patients. 
Others 




DNA / RNA 
20 exons, 8585 bp mRNA. 
Protein 
Encodes the 2285 amino acid AT-rich interactive 
domain-containing protein 1A (ARID1A); member of 
the SWI/SNF family; ARID1A possesses helicase and 
ATPase function and regulates transcriptional 
activation and repression of target genes through 
modification of the chromatin structure, including the 
MYC-oncogene (repression). 
Somatic mutations 
Somatic (truncating) mutations have been described n 
up to 10% of colorectal cancers, with more than half of 
these cases found to be associated with microsatellite 
instability (out-of-frame insertions or deletions at 
mononucleotide repeats).  
Recurrent inactivating genomic alterations have been 
confirmed in up to 37% of hypermutated cases in 
recent studies by the Cancer Genome Atlas Network; 
genomic alterations non-hypermutated CRC were 
infrequent (5%). 
STK11 (serine/threonine kinase 11) 
Location 
19p13.3 
DNA / RNA 
10 exons, 3276 bp mRNA. 
Protein 
Encodes a 433 amino acid protein.  
Tumor suppressor serine-threonine kinase, with 
important functions in the activation of adenine 
monophosphate-activated protein kinase (AMP)-
activated protein kinase kinases in the setting of energy 
deprivation; Activation of AMP kinases contributes to 
the maintenance of cell polarity and negatively 
regulates cell cycle progression and cell growth. 
Germinal mutations 
Mutations (Nonsense, missense, frameshift), result in 
the autosomal dominant Peutz-Jeghers syndrome, 
which results in the formation of benign 
hamartomatous polyps in the gastrointestinal tract; 
other characteristics include pigmented macules on the 
oral mucosa and lips.  
Patients with Peutz-Jeghers syndrome carry a severely 
increased risk for the development of CRC estimated  
about 39%. 
Somatic mutations 
Somatic mutations in STK11 are rare in sporadic 
colorectal cancer outside inherited hamartomatous 
syndromes. 
BMPR1A (bone morphogenetic protein 
receptor, type IA) 
Location 
10q22.3 
DNA / RNA 
13 exons, 3616 bp mRNA. 
Protein 
Encodes a 532 amino acid protein; Transmembrane 
serine-threonine kinase, type1 receptor, closely related 
to the ACVR1 and ACVR2 activin receptors; ligands 
include bone morphogenetic protein 2 and 4 (BMP-2 
and BMP-4) from the TGF-Beta superfamily. 
Germinal mutations 
Nonsense, missense, frameshift and splice-site 
mutations.  
Associated with Juvenile polyposis, which carries an 
approximate lifetime risk of 40% for development of 
CRC. 
MUTYH (mutY homolog (E. coli)) 
Location 
1p34.1 
DNA / RNA 
16 exons, 1839 bp mRNA. 
Protein 
DNA glycosylase.  
Functions in oxidative DNA damage repair (base 
excision repair), nicks A-G mismatches, as well as A-
8oxoG and A-C mismatches. 
Germinal mutations 
Tyr82-Cys and Gly253 -Asp transitions affect 
glycosylase activity, resulting in APC mutations in 
somatic cells. Nonsense mutations, missense and 
truncated protein mutations. Mutations cause 93-fold 
increase in colorectal cancer risk. 
DCC (deleted in colorectal carcinoma) 
Location 
18q21.3 
DNA / RNA 
29 exons, 4609 bp mRNA. 
Protein 
DCC is thought to be receptor for neptin-1 (axonal 
chemoattractant). In absence of ligand, it induces 
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Germinal mutations 
Chromosome 18 sequences are frequently (74%) lost in 
colorectal carcinoma. Loss of DCC is mostly observed 
in metastatic cancers. 
To be noted 
Note 
The RER+ sporadic colon cancers are mostly diploid, 
without LOH, with few mutations of p53 and APC and 
right-sided; they contain mutations in repetitive coding 
sequences of a number of genes such as the TGFbeta 
type II receptor, the receptor of the Insulin-like growth 
factor and the BAX gene implicated in apoptosis.  
The RER- are polyploid, with LOH (5q, 17p, 18q), 
mutations in p53, and more often left-sided, they have a 
worse prognosis. 
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